Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.08

-2.9%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (1226)	6/23/2000 6:23:00 PM
From: Pseudo Biologist	Read Replies (2) of 52153

In the category of "care to comment" (without knowing) ... Isn't it obvious? From your own citation: <<The cross-license agreement includes a worldwide royalty free cross-license to all issued and related patent applications pertaining to the generation of fully human monoclonal antibody technologies in genetically modified strains of mice. >> The cited patent was filed in 1995, so I don't see what the problem of interpretation could be here. BTW, the first inventor in this patent, Kucherlapati, is also one of the founders of MLNM. Always trying to tie up lines of discussion -g- PB

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next